Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand

BACKGROUND: Zidovudine (ZDV) has been associated with risk of haematological toxicity. Safety data from clinical trials is generally limited to 48 weeks. We assessed the short- and mid-term toxicity of ZDV/lamivudine (3TC) fixed-dose combination scored tablets in HIV-infected children followed in th...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Pharmacoepidemiology and Prescription
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350228/
https://www.ncbi.nlm.nih.gov/pubmed/28028587
http://dx.doi.org/10.1007/s00228-016-2182-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350228/
https://www.ncbi.nlm.nih.gov/pubmed/28028587
http://dx.doi.org/10.1007/s00228-016-2182-2

Ejemplares similares